Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Human Psychopharmacology|May 26, 2020
Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controlsEric M Pearlman, Darren Wilbraham, Ellen B Dennehy, et al.
Clinical Pharmacokinetics|February 10, 2021
Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with MigraineMax Tsai, Emel Serap Monkul Nery, Lisa Kerr, et al.
Psychosomatics|January 18, 2015
The importance of unresolved fatigue in depression: costs and comorbiditiesRebecca L Robinson, Judith J Stephenson, Ellen B Dennehy, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|April 23, 2013
Subscale validation of the neuropsychiatric inventory questionnaire: comparison of Alzheimer's disease neuroimaging initiative and national Alzheimer's coordinating center cohortsPaula T Trzepacz, Andrew Saykin, Peng Yu, et al.
Headache|December 4, 2019
The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of FindingsStewart J Tepper, Stephen D Silberstein, Noah L Rosen, et al.
The Journal of Headache and Pain|August 30, 2019
Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trialsRobert E Shapiro, Helen M Hochstetler, Ellen B Dennehy, et al.
Journal of Affective Disorders|August 19, 2008
The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BDLauren B Marangell, Ellen B Dennehy, Sachiko Miyahara, et al.
Clinical Trials (London, England)|July 10, 2009
Increasing minority research participation through collaboration with community outpatient clinics: the STEP-BD Community Partners ExperienceJane N Kogan, Mark S Bauer, Ellen B Dennehy, et al.
The Journal of Dermatological Treatment|October 21, 2016
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)Kristian Reich, Craig Leonardi, Mark Lebwohl, et al.
The Patient|January 24, 2015
Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2)Louis S Matza, Lindsey T Murray, Glenn A Phillips, et al.
Pageof 5